Newsletter

Blog

Contact Us

VivoScene

Sharing insights and stimulating conversations

Subscribe to Vivoscene

Special Edition Q3, 2022

Feature 66% of Diagnostic Biopsies for Common Skin Cancer can be Avoided Using Michelson Diagnostics’ VivoSight OCT Laser Scanner Major Netherlands study shows that VivoSight OCT is non-inferior to and more cost-effective than punch biopsy This new publication in The Lancet Oncology reports results from the study performed in the Netherlands at three dermatology centres ...
Newsletter image

March 2022

Latest News: Two Seminal Recent Articles Confirm Value of OCT for Basal Cell Carcinoma Authors identify the key OCT image characteristics and terminology for evidence-based, practical use in BCC management in clinical routine In the first article, published in JEADV by Fuchs et al.[1], a group of international OCT user experts agreed on a consensus ...
VS-NL-Landing-Mar-_22-B-Flat

November 2021

Latest News: Early Success Indication of Lengthy Onychomycosis Treatment through OCT Biomarkers Potential for significant cost savings from high predictive value of OCT imaging biomarkers Feature: Mount Sinai Icahn School of Medicine Department of Dermatology Invests in Latest State-of-the-Art Skin Imaging Technologies VivoSight OCT part of a multi-technology approach for skin cancer and beyond “With ...
Newsletter image